New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer

Amy M Weise, Shirish Gadgeel Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: Non-small-cell lung cancer (NSCLC) is a heterogeneous disease and a challenging malignancy to treat, as many patients have advanced disease at the time of diagnosis. R...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weise AM, Gadgeel S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c6b5e8573f5a4b288ba89c3869688421
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6b5e8573f5a4b288ba89c3869688421
record_format	dspace
spelling	oai:doaj.org-article:c6b5e8573f5a4b288ba89c38696884212021-12-02T01:21:05ZNew options in the management of intractable ALK(+) metastatic non-small-cell lung cancer1179-2728https://doaj.org/article/c6b5e8573f5a4b288ba89c38696884212014-08-01T00:00:00Zhttp://www.dovepress.com/new-options-in-the-management-of-intractable-alk-metastatic-non-small--peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728 Amy M Weise, Shirish Gadgeel Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: Non-small-cell lung cancer (NSCLC) is a heterogeneous disease and a challenging malignancy to treat, as many patients have advanced disease at the time of diagnosis. Recent advances have led to the identification of molecularly defined subtypes of NSCLC, namely for patients with adenocarcinoma histology. The most recently identified molecular target is the anaplastic lymphoma kinase (ALK) gene rearrangement, and patient responses to the ALK inhibitor crizotinib have led to its approval in this selected patient population. Like other tyrosine kinase inhibitors, resistance to crizotinib ultimately develops by various mechanisms requiring alternative therapeutic options. This review article discusses the management of patients with the ALK gene rearrangement, mechanisms of crizotinib resistance, and future potential therapeutic options. Keywords: non-small-cell lung cancer, disease management, cancer therapyWeise AMGadgeel SDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 35-42 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Weise AM Gadgeel S New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
description	Amy M Weise, Shirish Gadgeel Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: Non-small-cell lung cancer (NSCLC) is a heterogeneous disease and a challenging malignancy to treat, as many patients have advanced disease at the time of diagnosis. Recent advances have led to the identification of molecularly defined subtypes of NSCLC, namely for patients with adenocarcinoma histology. The most recently identified molecular target is the anaplastic lymphoma kinase (ALK) gene rearrangement, and patient responses to the ALK inhibitor crizotinib have led to its approval in this selected patient population. Like other tyrosine kinase inhibitors, resistance to crizotinib ultimately develops by various mechanisms requiring alternative therapeutic options. This review article discusses the management of patients with the ALK gene rearrangement, mechanisms of crizotinib resistance, and future potential therapeutic options. Keywords: non-small-cell lung cancer, disease management, cancer therapy
format	article
author	Weise AM Gadgeel S
author_facet	Weise AM Gadgeel S
author_sort	Weise AM
title	New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
title_short	New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
title_full	New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
title_fullStr	New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
title_full_unstemmed	New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
title_sort	new options in the management of intractable alk(+) metastatic non-small-cell lung cancer
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/c6b5e8573f5a4b288ba89c3869688421
work_keys_str_mv	AT weiseam newoptionsinthemanagementofintractablealkmetastaticnonsmallcelllungcancer AT gadgeels newoptionsinthemanagementofintractablealkmetastaticnonsmallcelllungcancer
_version_	1718403162739572736

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer

Ejemplares similares